NCT03225716 2024-05-03
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 1 Terminated
Clinical Trials
3 trialsNCT01359657 2016-03-16
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Completed
NCT01120457 2015-03-06
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Bristol-Myers Squibb
Phase 1 Completed